Dr. Ali Al-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held a meeting with representatives of pharmaceutical distribution companies, in the presence of Dr. Gamal El-Leithy, Chairman of the Chamber of Pharmaceutical Industry, to discuss the latest updates on the pharmaceutical Track and Trace project and respond to inquiries related to its implementation within local manufacturing and distribution companies.
This initiative is part of the EDA's efforts to bolster the digital transformation system and enhance the efficiency of oversight on the Egyptian pharmaceutical market.
The discussions reviewed the progress made in implementing the project—one of the most significant digital transformation initiatives within Egypt’s pharmaceutical system—and examined the stages of execution, as well as the mechanisms of supporting manufacturers and distributors to ensure the effective application of the system. The system aims to enhance pharmaceutical products' traceability, increase transparency, and ensure the safety and integrity of pharmaceutical products available to Egyptian patients.
Dr. Al-Ghamrawy explained that the new traceability system is designed to ensure complete monitoring of a pharmaceutical product’s path from production to patient use, thereby guaranteeing product safety and protecting citizens from counterfeit or substandard products.
He emphasized the importance of joint coordination among all stakeholders in the pharmaceutical ecosystem to achieve integrated project implementation according to the established timeline.
Representatives of the distribution companies affirmed their commitment to supporting the EDA’s efforts in implementing the traceability project, describing it as a milestone in developing Egypt’s pharmaceutical supply chain system and improving operational efficiency, emphasizing that the private sector is a fundamental partner in the project’s success and that companies are already working to upgrade their internal infrastructure to meet the system’s technical requirements—helping ensure the availability of safe and effective pharmaceutical products for patients.
The company representatives also praised the EDA’s leadership role in driving the project forward, describing the Authority as a model institution in planning, implementation, and stakeholder communication in the pharmaceutical sector. They valued the EDA's commitment to providing technical assistance and resolving operational challenges, reflecting a genuine commitment to public-private partnership in achieving national pharmaceutical goals.
The meeting was attended on behalf of the Egyptian Drug Authority by:
• Dr. Tamer El-Hossieny, Vice Chairman of the Egyptian Drug Authority
• Dr. Ahmed Abou Taleb, Financial Advisor of the Egyptian Drug Authority
• Counselor Sherif Magdy, Vice President of the State Council and Legal Advisor of the Egyptian Drug Authority
• Dr. Amany Gawdat, Associate to the EDA Chairman and Supervisor of the Central Administration of the Chairman’s Office
• Dr. Osama Hatem, Associate to the EDA Chairman for Policy and International Cooperation and Supervisor of the Central Administration of Pharmaceutical Policies and Market Access
• Dr. Amira Mahjoub, Head of the Central Administration for Inspection on Pharmaceutical Establishments
• Dr. Hossam Abdallah, Associate to the EDA Chairman and General Manager of the General Administration for Market Support and Business Continuity
• Brigadier Mohamed Tantawy, Supervisor of Digital Transformation and Automation Projects
This meeting is part of a series of gatherings held by the Authority with stakeholders operating in the pharmaceutical market to ensure efficient implementation, adherence to specified standards, and compliance within the framework of applying the pharmaceutical tracking project.
The meeting was also attended by representatives of major pharmaceutical distribution companies, including:
• Dr. Mahmoud Abdel-Gawad, Chief Executive Officer, Ibn Sina Pharma
• Dr. Walid Saada, Chief Executive Officer of Supply Chains, Egyptian Company for Drug Trade (EGYDRUG)
• Dr. Mohamed Gazarine, Chairman of the Board, Pharma Overseas
• Dr. Mohamed El-Samman, Head of Supply Chain, Viatris Egypt
• Dr. Mai Ali, Supply Chain Quality Manager, Viatris Egypt
• Dr. William Mahany, Chairman of the Board, Ramco Pharma
• Dr. Ramez Mahany, Vice Chairman of the Board, Ramco Pharma
• Dr. Ahmed Sami, Representative, Pharma Overseas
• Dr. Manal Hamdy, Manager of Internal Control, Akhnaton
• Dr. Amr Ali, Managing Director, Ebdaa for Pharmaceutical Trading and Distribution
From DAF Company, attendees included Eng. Basel Mubarak, Chairman of the Board; Eng. Hatem Kandil, Chief Executive Officer; Eng. Safwat Hamad; and Eng. Sama Taleb.
In conclusion, participants reaffirmed their full commitment to joint cooperation to ensure the successful implementation of the project and the alignment of all efforts toward its realization.
The meeting highlighted Egypt’s continued progress toward digitizing and regulating the pharmaceutical market, reinforcing its leadership role in pharmaceutical governance and supporting national objectives to protect public health and strengthen pharmaceutical security.